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Abstract
Purpose The goal of this study was to synthesize evidence
comparing cancer screening receipt between cancer survi-
vors and non-cancer controls by conducting a systematic
review and meta-analysis.
Methods We searched PubMed, EMBASE, and CINAHL
databases from inception through April 1, 2010 using search
terms related to cancer, survivorship, and cancer screening.
Studies were included if they reported a comparison of
cancer screening receipt between cancer survivors and
non-cancer controls. We performed a meta-analysis on the
effect of cancer survivorship on breast, cervical, colorectal,
and prostate cancer screening receipt.
Results Our search strategy identified 1,778 titles, of which
20 met our inclusion/exclusion criteria. In our meta-analyses,
cancer survivors were more likely to be screened for breast,
cervical, colorectal, and prostate cancer than non-cancer con-
trols (pooled odds ratio, 1.27; 95 % CI, 1.19–1.36). We
observed significant heterogeneity between studies, most of
which remained unexplained after subgroup and sensitivity
analyses. Important contextual factors, such as how screening
programs operate, were not reported in the primary literature.
Many cancer survivors (along with non-cancer controls) still
did not receive cancer screening.
Conclusion Compared with non-cancer controls, cancer sur-
vivors receive more frequent screening for new primary
breast, cervical, colorectal, and prostate cancers. Future
research should seek to determine whether increased uptake
of cancer screening is associated with improved outcomes
during cancer survivorship.
Implications for Cancer Survivors Our systematic review
and meta-analysis demonstrated that cancer survivors re-
ceived more frequent screening for second primary breast,
cervical, colorectal, and prostate cancers than non-cancer
controls. As many cancer survivors are at an increased risk
of developing a second primary cancer, future research
should seek to determine whether this increased uptake of
cancer screening in cancer survivors leads to improved out-
comes during cancer survivorship.
Keywords Early detection of cancer . Neoplasms .
Second primary cancer . Survivors . Systematic review
Introduction
A current and future challenge for healthcare systems is to
determine how to best provide long-term follow-up care to the
growing prevalence of cancer survivors, estimated to number
over 28 million worldwide [1]. An often overlooked, but
nonetheless important, component of follow-up care for can-
cer survivors is screening for new primary cancers [2]. For
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most malignancies, a cancer survivor’s risk of develop-
ing a second primary cancer is at least as great as the
general population. The epidemiology of second primary
cancers is complex, and is a function of common risk
factors, genetic links, and late carcinogenic effects from
treatment of the primary cancer [3]. Among cancer survi-
vors, often the risk of developing a second primary cancer
at a different anatomical site can be much greater than
the general population [4–9].
Conflicting theories suggest that cancer survivors, as
individuals with a comorbid condition, may be either
more or less likely to receive preventive care. One theory
[10] and several researchers [11–13] have hypothesized
that cancer survivors may receive more frequent screen-
ing due to increased contact with the healthcare system.
Increased contact with the healthcare system and a rec-
ommendation from a primary care physician are both
strongly associated with the uptake of cancer screening
in the general population [14–17]. Conversely, the com-
peting demands model [18] and other researchers [19,
20] have hypothesized that despite an increased amount
of contact with the healthcare system, a cancer survivor’s
previous cancer diagnosis may shift healthcare workers’
attention away from other preventive health services such
as screening for new primary cancers.
While two prior systematic reviews have compared re-
ceipt of general preventive healthcare (including cancer
screening) in cancer survivors and the general population
[21, 22], the volume of available literature has substantially
increased since these reviews were published. In addition,
these two reviews reached conflicting conclusions, with
Wilkins and Woodgate concluding “the prevalence of sec-
ondary prevention practices among cancer survivors is gen-
erally lower than recommended” [22], but Khan et al.
concluding “cancer screening is generally well managed
through normal channels and is adequate amongst survivors
of adult cancer in the United States” [21]. An additional
review by Treanor and Donnelly assessed health services
utilization among cancer survivors, concluding “Overall,
there is a need to improve access to care for all cancer
survivors” [23]. However, this review did not compare
health services utilization between cancer survivors and
the general population. Given the conflicting results of these
prior reviews, the objective of this review was to synthesize
evidence comparing cancer screening receipt between can-
cer survivors and non-cancer controls.
Methods
To evaluate the above objective, we conducted a systematic
review using methods similar to those advocated by the
Cochrane Collaboration [24]. We systematically identified
and included observational studies that compared the receipt
of any cancer screening test between cancer survivor and
non-cancer control group populations. Our research ques-
tion was developed and refined in consultation with
healthcare professionals, program managers/administrators,
and other decision makers and stakeholders from the cancer
care community during interactive workshops.
Data sources and search strategy
We searched three electronic databases (PubMed, EMBASE,
and CINAHL; all available years to April 1, 2010) using a
combination of MeSH terms and keywords relating to cancer,
cancer survivorship, and cancer screening. The PubMed
search strategy is available in the Appendix; the EMBASE
and CINAHL search strategies used similar terms. No date or
language restrictions were used in the search strategy. Refer-
ence lists of included studies and previous reviews were
screened to identify additional articles. Previous reviews were
identified through our search strategy.
Study selection and data abstraction
Studies that measured and compared the receipt of cancer
screening in both cancer survivor and a non-cancer con-
trol group were included in this review. We included all
definitions of a cancer survivor in this study, regardless
of time since diagnosis or initial cancer site. We included
studies of both adult and childhood cancer survivors.
Secondary survivors, e.g., family members of the cancer
survivor, were not eligible for inclusion in this review.
All cancer screening sites and tests were eligible for
inclusion, regardless of whether the screening was oppor-
tunistic or programmatic in nature. Studies that measured
screening receipt outside of commonly recommended age
ranges were included and explored with subgroup analy-
sis. Unpublished literature was sought through contact
with content experts.
A standardized study selection and data abstraction form
was used. The initial literature screen of titles and abstracts
was done by one author (MC) in order to remove citations
that were clearly not relevant to the study objectives. Appli-
cation of the study inclusion criteria to the full-text articles
and abstraction of included articles was conducted indepen-
dently by two reviewers (MC, CS) with formal systematic
review training. If necessary, disagreements were resolved
through consensus and consultation with a third reviewer
(JH). If available, appropriately adjusted odds ratios were
favoured over unadjusted estimates. If odds ratio estimates
were not reported in the primary study, crude odds ratios
were calculated from raw data. Data for individual screening
tests [for example, fecal occult blood testing (FOBT) and
endoscopy for colorectal cancer screening] were recorded
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separately whenever possible. Study authors were contacted
to retrieve missing data.
Risk of bias assessment
Study level risk of bias was assessed using four categories
selected from quality assessment tools used to assess
prognosis studies and randomized controlled trials of in-
tervention effectiveness [25, 26], and modified to fit the
review question and types of observational studies includ-
ed in this review. These four risk of bias categories used
were: (1) Selection bias; (2) Definition of cancer survivor-
ship [low: long-term survivors (all ≥5 years); moderate:
majority long-term survivors; high: time since diagnosis
not measured or short-term survivors]; (3) Measurement
of screening receipt (low: administrative data; moderate:
self-report); and (4) Adjustment for confounding or use of a
matched cohort. These risk of bias assessments were used to
guide sensitivity analyses. Other categories explored in our
subgroup and sensitivity analyses include the use of an
exclusively elderly population (greater than age 65), the use
of a childhood cancer survivor population, and the use of
upper and/or lower age limits reflecting screening guidelines.
Analysis
We performed a meta-analysis on the effect of cancer sur-
vivorship on breast, cervical, colorectal, and prostate cancer
screening receipt, supplemented with a thoughtful narrative
discussion. Odds ratio effect estimates by cancer site and
screening rate were pooled using a random effect generic
inverse variance model with Review Manager 5.0 (Cochrane
Collaboration, Oxford, UK) software. Meta-analyses were
not conducted for skin and testicular cancer screening due to
the small number of studies reporting these outcomes (n=1
and n=2, respectively).
An overall summary estimate of the association between
cancer survivorship and cancer screening was calculated
using data from all included studies and any screening site.
We selected and pooled the single odds ratio estimate from
each included study that represented the screening site with
the lowest standard error. This decision rule was determined
a priori, and selected to minimize possible selection bias.
Heterogeneity was measured using the I2 statistic [24]. The
narrative synthesis included studies which could not be
quantitatively combined and analyzed, results from the risk
of bias assessment, and other potential sources of heteroge-
neity from the meta-analysis, such as study-level demo-
graphic and cancer survivor information.
When a study separately reported two different screening
tests for a single cancer site, our decision rule was to choose
the screening test we felt was more likely to be included in a
programmatic, population-level screening intervention for
that site. For example, in studies that separately reported
the receipt of FOBT and endoscopy colorectal cancer
screening, we included the FOBT screening test estimate
in the colorectal cancer screening overall estimate. When
multiple studies presented data from the same cohort, we
avoided double counting participants by only including the
single study with the largest sample size in the meta-
analysis. Sensitivity analyses were conducted to determine
whether changing these decision rules modified our results.
Results
The flow of study selection and reasons for full-text article
exclusion are presented in Fig. 1. Table 1 summarizes the
characteristics of the 20 studies which met our inclusion
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criteria [11–13, 19, 20, 27–41]. Forty-eight cancer screening
sites were reported in these studies: 14 breast, 11 cervical,
11 colorectal, 6 prostate, 1 skin, and 2 testicular. Only one
study was conducted outside North America [32], which
was conducted in the United Kingdom. Three overlapping
study data sources were observed: the National Health In-
terview Survey [13, 28]; the Ontario Cancer Registry [30,
32]; and the Childhood Cancer Survivor Study [37, 40].
The demographics of the cancer survivors in the included
studies varied greatly, and ranged from childhood cancer sur-
vivors to elderly populations. The predominant ethnicity, when
reported, was white/Caucasian, with only one study focusing
on an ethnic minority [27], which was Hispanic. Most studies
contained survivor populations with mixed initial cancer diag-
nosis types (n=10); the most common single initial cancer
diagnosis type reported upon was breast cancer (n=5).
Mammography was used for breast cancer screening in all
studies except one which measured receipt of either a clinical
breast examination or mammogram [11]. Cervical cancer
screening consisted of the receipt of a Pap smear in all studies.
Colorectal cancer screening consisted of the receipt of FOBT,
endoscopy procedures (colonoscopy, sigmoidoscopy, or
proctoscopy), barium enema, or some combination of these
three. Prostate cancer screening consisted of the receipt of a
prostate specific antigen (PSA) test in all studies, except one
that measured receipt of either a PSA or digital rectal
examination.
The screening timeframes varied greatly between studies,
and ranged from within the last 12 months to ever/never being
screened. The most common screening timeframes were:
breast cancer screening (2-year interval, 7/14 studies), cervical
cancer screening (3-year interval, 7/14 studies), colorectal
cancer screening (FOBT, 1-year interval, 4/9 studies; endos-
copy, 5- or 10-year intervals, 4/11 studies), and prostate cancer
screening (1-year interval, 4/6 studies). The proportion of
cancer survivors and controls screened varied greatly between
studies, and appeared to be influenced by the age of the
participants in each study, the length of screening timeframe
(longer screening timeframes resulted in a greater proportion
of both cancer survivors and controls receiving screening),
Table 1 Characteristics of included studies
Characteristics of Included Studies















Aparicio-Ting [27] 2003 USA 112/ 2062 34% between age 50-64, 100% female, 100% Hispanic Mixed CS SR SR
Bellizzi [28] 2005 USA 7,384 / 121,347 52.7% ≥ age 65, 60.6% female, 88.5% 
white ethnicity Mixed CS SR SR
Bishop [11] 2010 North America 662 / 158 Caucasian ethnicity Mixed CS AD SR
Breslau [12] 2010 USA 1,502 / 31,911 
white ethnicity Breast Cancer CS SR SR
Duffy [19] 2006 USA 85 / 340 Caucasian /other ethnicity Breast Cancer CS SR SR
Earle [29] 2003 USA 5,965 / 6,062 
white ethnicity Breast Cancer RC AD AD
Earle [20] 2004 USA 14,884 / 16,659
white ethnicity Colorectal Cancer RC AD AD
Grunfeld [30] n/a Canada 21,111/ 105,340 Mean age: 58.6, 86% female, no 
ethnic information Mixed RC AD AD
Hudson [41] 2009 USA 109 / 641 Mean age: 68.7, 59% female, 80% 
white ethnicity Mixed CS SR SR + CR
Khan [31] 2010 United Kingdom 29,244 / 116,418 Mean age: 70.7, 73.4% female, no 
ethnic information Mixed RC AD AD
Kwon [32] 2009 Canada 3,473 / n/a information Endometrial Cancer RC AD AD
Mayer [33] 2007 USA 619 / 2,141
white ethnicity Mixed CS SR SR
McBean [35] 2008 USA 14,575 / 14,575 31.9% between ages 67-74, 100% female, 94.3% white ethnicity Uterine Cancer RC AD AD
McBean [34] 2009 USA 7,666 / 36,433
white ethnicity Colorectal Cancer RC AD AD
Ng [36] 2008 USA 511 / 224 Median age: 44, 51% female, no 
ethnic information available Hodgkin's Lymphoma CS AD SR
Oeffinger† [37] 2009 North America
551 / 622 100% female, 92.4% white
Mixed CS AD SR
561 / 622 50, 100% female, 93.2% white
Snyder (a) [39] 2009 USA 1961 / 1961
white ethnicity Breast Cancer RC AD AD
Snyder (b) [38] 2009 USA 23,731 /  47,127‡†
white ethnicity Breast Cancer RC AD AD
Trask [13] 2005 USA 2,151 / 30,195
white ethnicity Mixed CS SR SR
Yeazel [40] 2004 North America 9,434 / 2,667
ethnic information Mixed CS AD SR
No Chest RT: 45.8% between ages 40- 
Chest RT: 46.3% between ages 40-50, 
Mean age: 75, 100% female, 90% 
Mean age: 75.7, 100% female, 90% 
Mean age: 61.9, 59.7% female, 90% 
No age information, 46.8% female, no 
Mean age: 58, 65.5% female, 81.5% 
Mean age: 73.6, 100% female, 85% 
Mean age: 66.8, 100% female, 76.3% 
Mean age: 61.7, 100% female, 85.9% 
Mean age: 78.7, 100% female, 89% 
Mean age: 79.9, 57.6% female, 86.4% 
Median age: 49.1, 62% female, 92% 
Number of Participants
Cancer Sites Screened For
Mean age: 63, 100% female, no ethnic 
CS Cross-Sectional Survey, RC Retrospective Cohort Study, SR Self-Reported exposure/outcome, AD Administratively determined exposure/
outcome, CR Chart Review
a Study contained two cancer survivor groups: one survivor cohort received chest radiotherapy, the other did not
b Study contained two controls groups: 23,731 controls with mammogram in same year as survivor’s dx., 23,396 controls with the same
comorbidity score
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and screening site (lower screening rates for colorectal cancer
than breast or cervical cancer). Across all screening sites, a
large proportion of both cancer survivors and non-cancer
controls did not receive adequate screening for new primary
cancers, as defined by the screening recommendations used in
each primary study.
Cancer survivors were more likely to receive screening
for new primary cancers than non-cancer controls across all
four cancer sites where a meta-analysis was conducted, as
well as for skin and testicular cancer screening. Across all
studies, cancer survivors were 27 % more likely to receive
screening for new primary cancers compared to non-cancer
controls [odds ratio (OR), 1.27; 95 % confidence interval
(CI), 1.19–1.36]. Meta-analyses for breast, cervical, colo-
rectal, and prostate cancer screening can be seen in Fig. 2.
Cancer survivors were 19 % more likely to receive breast
cancer screening (OR, 1.19; 95 % CI, 1.06–1.34), 22 %
more likely to receive cervical cancer screening (OR, 1.22;
95 % CI, 1.12–1.33), 19 % more likely to receive colorectal
cancer screening (OR, 1.19; 95 % CI, 1.10–1.30), and 22 %
more likely to receive prostate cancer screening (OR, 1.22;
95 % CI, 1.10–1.36).
Two studies could not be incorporated into our meta-
analyses. Duffy et al. [19] used different definitions of
Fig. 2 Meta analyses for
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appropriate cervical cancer screening in their cancer survivor
(annual screening) and non-cancer control (biennial screening)
groups, and reported that cancer survivors were as likely to
receive an annual Pap smear as non-cancer survivors were to
receive a biennial Pap smear (OR, 0.98; 95 % CI, 0.60–1.60).
Kwon et al. [32] compared receipt of breast and cervical cancer
screening among cancer survivors to a general population
screening rate, and found that cancer survivors were about twice
as likely to receive breast cancer screening (cancer survivors,
64%; general population, 31%) and colorectal cancer screening
(cancer survivors, 30 %; general population, 15 %) during their
study follow-up period.We did not include Kwon et al. [32] into
our meta-analyses for two reasons: first, the study population
overlapped with the study by Grunfeld et al. [30], which was
larger; second, this was the only included study that used general
population screening rates as a comparison group.
There was significant heterogeneity observed between stud-
ies for breast (n=11), cervical (n=11), and colorectal (n=9)
screening sites (I2=89 %, 75 %, and 87 % respectively). No
single study accounted for the statistically significant hetero-
geneity for these sites. There was no significant heterogeneity
observed between the five studies for prostate cancer screening
Table 2 Sensitivity and subgroup analyses for breast, cervical, and colorectal cancer screening
Breast cancer screening Cervical cancer cancer screening Colorectal cancer screening
Summary odds ratio estimate (95 % CI)
All studies 1.19 (1.06–1.34) 1.22 (1.12–1.33) 1.19 (1.10–1.30)
n=11 n=11 n=9
Study characteristics
Elderly population (65+) 1.12 (0.91–1.37) 1.26 (1.18–1.34) 1.23 (1.08–1.40)
n=3 n=2 n=3
Non-elderly population 1.24 (1.05–1.46) 1.19 (1.04–1.36) 1.16 (1.05–1.29)
n=8 n=9 n=6
Childhood cancer survivors 1.17 (0.41–3.28) 0.87 (0.53–1.43) 0.66 (0.40–1.10)
n=2 n=3 n=1
Non-childhood cancer survivors 1.15 (1.02–1.28) 1.28 (1.22–1.34) 1.21 (1.11–1.31)
n=9 n=8 n=8
Ages of cancer survivors/controls within screening guidelines
Adequate lower and upper age limits 1.06 (0.95–1.19) 1.14 (0.95–1.37) 1.11 (1.06–1.17)
n=5 n=4 n=1
No lower and upper age limits 1.34 (1.13–1.59) 1.28 (1.16–1.41) 1.21 (1.10–1.33)
n=6 n=7 n=8
Risk of bias categories
(1) Selection bias
Low/moderate risk 1.16 (1.02–1.30) 1.27 (1.21–1.33) 1.22 (1.11–1.34)
n=7 n=6 n=5
High risk 1.25 (0.78–2.02) 1.08 (0.70–1.65) 1.14 (0.92–1.42)
n=4 n=5 n=4
(2) Adequate cancer survivor selection
Low/moderate risk 1.23 (1.09–1.40) 1.22 (1.12–1.33) 1.18 (1.09–1.29)
n=9 n=10 n=7
High risk 0.96 (0.78–1.17) 1.50 (0.67–3.37) 1.21 (0.99–1.47)
n=2 n=1 n=2
(3) Screening measurement
Administrative data 1.14 (0.99–1.30) 1.26 (1.19–1.33) 1.20 (1.08–1.33)
n=5 n=4 n=4
Self-reported 1.22 (0.93–1.61) 1.16 (0.87–1.54) 1.19 (1.00–1.43)
n=6 n=7 n=5
(4) Controlling for confounding/using a matched cohort
Low/moderate risk 1.22 (1.02–1.38) 1.24 (1.15–1.34) 1.21 (1.11–1.31)
n=9 n=9 n=8
Unadjusted studies (high risk) 0.65 (0.37–1.15) 0.87 (0.33–2.29) 0.66 (0.40–1.10)
n=2 n=2 n=1
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(I2=34 %, p=0.19), and therefore, we did not conduct sub-
group or sensitivity analyses for prostate cancer screening.
Risk of bias varied considerably between studies, ranging
from studies using linked administrative databases with low risk
of selection and measurement bias, to higher risk of bias studies
using responses from self-reported surveys. Most studies using
self-reported surveys had low response rates, introducing a
further potential source of bias. There was considerable varia-
tion between studies’ lengths of cancer survivorship follow-up,
with some studies exclusively focusing on long-term survivors,
while others contained a wide range of cancer survivorship
follow-up time. Risk of bias assessments for each individual
study are available by contacting the authors.
To explore potential sources of heterogeneity in the breast,
cervical, and colorectal cancer screening meta-analyses, we
conducted several sensitivity and subgroup analyses, presented
in Table 2. Two categories were found to be statistically signif-
icantly different in colorectal cancer screening: studies that did
not control for confounding or use a matched cohort, and
studies that used a cohort of childhood cancer survivors. These
differences were localized to a single study, and are unlikely to
be a clinically significant source of heterogeneity. No other
statistically significant subgroup or sensitivity analyses were
found. There was no significant effect on our overall meta-
analysis results when we conducted a sensitivity analysis by
changing our decision rule to exclude studies with overlapping
study populations.
Discussion
Our meta-analyses indicate that cancer survivors were more
likely to receive screening for new primary cancers across all
screening sites included in this review (19 % more likely to
receive breast and colorectal cancer screening, 22 % more
likely to receive cervical and prostate cancer screening). Tak-
ing the effect estimate with the lowest standard error from all
studies included in our meta-analysis, cancer survivors overall
were 27 % more likely to receive screening for new primary
cancers.
While cancer survivors were more likely to receive
screening for new primary cancers at each of the screening
sites reported in this review, this finding must be interpreted
in light of the receipt of cancer screening as a whole. Studies
in our review reported that many individuals from both the
general population and cancer survivor subpopulation did
not receive screening tests recommended for the detection of
new primary cancers.
Our study has several strengths. We used a rigorous
search strategy which identified a yet-to-be published pri-
mary study. We were able to use two authors to abstract data
in an effort to minimize data abstraction errors. Our meta-
analysis and sensitivity/subgroup analyses were planned a
priori. Finally, we tailored our review question and reporting
of results to meet the needs of healthcare professionals,
program managers/administrators, and other decision
makers by holding interactive workshops with key stake-
holders throughout the review process.
Our study limitations largely mirror the limitations of the
included literature. As only 20 studies were identified, sub-
group and sensitivity analyses were likely underpowered to
detect potential differences. Important contextual factors were
not available for analysis in our systematic review, such as
how screening programs local to each study operate (e.g.,
whether screening programs actively target specific age
groups, or depend on primary care- or self-referral), and the
degree to which follow-up care is integrated with cancer
screening programs. These contextual factors could be a po-
tential source of hidden heterogeneity in our study. Many
studies contained incomplete information, which we were
mostly able to overcome through contact with study authors.
Few studies reported results separately for short- or long-term
cancer survivors. Some studies did not use upper or lower age
limits to compare receipt of cancer screening between cancer
survivors and non-cancer controls. There were inconsistencies
between studies’ use of screening timeframes, which often did
not reflect national recommendations for population-based
cancer screening. As the studies included in our systematic
review are predominantly from the USA, it is unclear whether
the summary estimates in this study are applicable to other
healthcare systems.
We conducted a subgroup analysis to examine whether
cancer survivors might have higher uptake of cancer screening
outside typical age restricted screening recommendations
compared to non-cancer controls. This could have presented
a source of bias in studies which did not use an upper age
restriction. Healthcare providers or cancer survivors may rec-
ognize that cancer survivors are at a greater risk, and recom-
mend starting or ending screening at earlier/later ages
compared to the general population. However, our subgroup
analysis found that studies without upper or lower age re-
strictions were not a significant source of heterogeneity. This
finding is mirrored in studies that only contained an exclu-
sively elderly population (≥ age 65), where we observed no
significant difference in screening receipt. Future research
should compare the receipt of screening within and outside
guideline-based age recommendations to further explore
whether the differences in screening uptake exclusively occur
outside screening guideline age recommendations.
The two studies that were not included in our meta-analyses
appeared to reach similar conclusions as the included literature.
Despite using an annual screening timeframe for cancer survi-
vors, and a biennial screening timeframe for non-cancer con-
trols, Duffy et al. [19] found that cancer survivors were as likely
to receive annual screening as non-cancer controls were to
receive biennial screening. This suggests that if similar
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screening timeframes were used for these two populations,
cancer survivors would be screened more frequently than
non-cancer controls. Kwon et al. [32] reported absolute screen-
ing differences that were much greater than any other study
included in our review. This finding may be influenced by the
researchers not restricting their analysis to guideline-based age
recommendations, the inclusion of many survivors outside of
screening age recommendations, and their comparison group
being age-standardized general population screening rates.
In the absence of evidence which directly examines screen-
ing efficacy among cancer survivors, several studies have dem-
onstrated that many cancer survivor populations are at an
increased risk of developing second primary cancers [4–9].
Long-term cancer survivors, or short-term cancer survivors
who are likely to survive long term based on the clinical
characteristics of their disease, should be encouraged to meet
population-based screening recommendations. Future research
should directly measure the efficacy and cost-effectiveness of
cancer screening among cancer survivors, and also seek to
determine whether the optimal screening frequency for cancer
survivors differs from the general population.
No studies in this review reported attempts to implement
interventions to increase cancer screening receipt among cancer
survivors. As cancer survivors represent a high-risk population,
such interventions could have an impact on reducing the like-
lihood of cancer survivors being diagnosed with late-stage
second primary cancers. Interventions that have been shown
to increase screening uptake in the general population include:
reminders, small media (e.g., videos and printed materials),
one-on-one education, and reducing structural barriers (e.g.,
reducing travel distances and increasing hours of operation)
[42]. Providing healthcare providers with assessment and feed-
back has also been shown to increase screening rates [42]. It is
possible that these same interventions would increase the up-
take of cancer screening among cancer survivors as well.
In conclusion, this study demonstrates that cancer survi-
vors, a population that may be at a greater risk of developing
a new primary cancer, are more likely to receive screening
for new primary cancers than non-cancer controls. These
results should be interpreted in light of suboptimal cancer
screening rates in both cancer survivors and the general
population. Whether increasing uptake of cancer screening
is associated with improved outcomes during the cancer
survivorship period should be a focus of future research.
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